RD-ConnectRD-Connect

  • About
    • Introduction to rare diseases
    • Structure
      • Executive Management Committee (EMC)
      • Scientific Advisory Board (SAB)
      • Patient Advisory Council (PAC)
      • Rare Disease Patient and Ethics Council (RD-PEC)
      • Panel for Biobank Assessment
    • Collaborations
  • What we do
    • Data linkage
      • FAIRification of rare disease registries
      • Linked data and ontology task force
      • Ontologies in rare disease registries
    • Omics data
      • Genome-Phenome Analysis Platform
    • Phenotypic data
      • Registry & Biobank Finder for patient registries
      • Registry common data elements
      • Core Implementation Group
    • Biosamples data
      • Registry & Biobank Finder for biobanks
      • Sample Catalogue
      • Biobank assessment process
      • Biobank Assessment Panel
    • Bioinformatic tools
    • Ethical, Legal and Social Issues (ELSI)
      • Sharing of biosamples and data
      • Standards for informed consent
      • Response to the EU General Data Protection Regulation (GDPR)
    • Patient engagement
  • Resources
    • Newsletters
    • Scientific publications
    • Forms and guides
    • Presentations and flyers
    • Periodic activity reports
    • Glossary
  • For Patients and Families
  • News
  • Events
  • Contact
    • Coordination office
    • Contacts Directory
    • Organisations Directory
VISIT THE PLATFORM
  • Home
  • Publication
  • Impaired Presynaptic High-Affinity Choline Transporter Causes a Congenital Myasthenic Syndrome with Episodic Apnea
 

Impaired Presynaptic High-Affinity Choline Transporter Causes a Congenital Myasthenic Syndrome with Episodic Apnea

RD-Connect

An integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. Visit the platform:

Go to analysis platform

Go to registries and biobanks catalogue

Go to biosamples catalogue

See all publications

Impaired Presynaptic High-Affinity Choline Transporter Causes a Congenital Myasthenic Syndrome with Episodic Apnea

Author(s): Bauche S, O’Regan S, Azuma Y, Laffargue F, McMacken G, Sternberg D, Brochier G, Buon C, Nassima Bouzidi N, Topf A, Lacene E, Remerand G, Beaufrere AM, Pebrel-Richard C, Thevenon J, El Chehadeh-Djebbar S, Faivre L, Duffourd Y, Ricci F, Mongini T, Fiorillo C, Astrea G, Magdalena Burloiu C, Butoianu N, Sandu C, Servais L, Bonne G, Nelson I, Desguerre I, Nougues MC, Boeuf B, Romero N, Laporte J, Boland A, Lechner D, Deleuze JF, Fontaine B, Strochlic L, Lochmuller H, Eymard B, Mayer M, Nicole S
Published: September 1, 2016
Journal: American Journal of Human Genetics
DOI: 10.1016/j.ajhg.2016.06.033

Go to publication

Abstract:

The neuromuscular junction (NMJ) is one of the best-studied cholinergic synapses. Inherited defects of peripheral neurotransmission result in congenital myasthenic syndromes (CMSs), a clinically and genetically heterogeneous group of rare diseases with fluctuating fatigable muscle weakness as the clinical hallmark. Whole-exome sequencing and Sanger sequencing in six unrelated families identified compound heterozygous and homozygous mutations in SLC5A7 encoding the presynaptic sodium dependent high-affinity choline transporter 1 (CHT), which is known to be mutated in one dominant form of distal motor neuronopathy (DHMN7A). We identified 11 recessive mutations in SLC5A7 that were associated with a spectrum of severe muscle weakness ranging from a lethal antenatal form of arthrogryposis and severe hypotonia to a neonatal form of CMS with episodic apnea and a favorable prognosis when well managed at the clinical level. As expected given the critical role of CHT for multisystemic cholinergic neurotransmission, autonomic dysfunctions were reported in the antenatal form and cognitive impairment was noticed in half of the persons with the neonatal form. The missense mutations induced a near complete loss of function of CHT activity in cell models. At the human NMJ, a delay in synaptic maturation and an altered maintenance were observed in the antenatal and neonatal forms, respectively. Increased synaptic expression of butyrylcholinesterase was also observed, exposing the dysfunction of cholinergic metabolism when CHT is deficient in vivo. This work broadens the clinical spectrum of human diseases resulting from reduced CHTactivity and highlights the complexityof cholinergic metabolism at the synapse.

Visit the platform

Go to Genome-Phenome Analysis Platform

Go to Registry & Biobank Finder

Go to Sample Catalogue

Newsletter Signup

Recent news

RD-Connect Genome-Phenome Analysis Platform is an IRDiRC Recommended Resource

Published: April 5, 2018

RD-Connect in press

Published: March 1, 2018

Today is the Rare Disease Day 2018

Published: February 28, 2018

Key RD-Connect, NeurOmics and EURenOmics publication

Published: February 27, 2018

RD-Connect and EURenOmics among the DG Research success stories

Published: February 15, 2018

Social

An integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. Visit the platform:

Genome-Phenome Analysis Platform

Analyse and share genomic data

Registry & Biobank Finder

Directory of rare disease biobanks and patient registries

Sample Catalogue

Browse rare disease biosamples stored in biobanks

Sitemap

  • NEWS
  • EVENTS
  • CONTACT
    • Coordination office
    • Contacts Directory
    • Organisations Directory
  • About
    • Introduction to rare diseases
    • Structure
      • Executive Management Committee (EMC)
      • Scientific Advisory Board (SAB)
      • Patient Advisory Council (PAC)
      • Rare Disease Patient and Ethics Council (RD-PEC)
      • Panel for Biobank Assessment
    • Collaborations
  • What we do
    • Data linkage
      • FAIRification of rare disease registries
      • Linked data and ontology task force
      • Ontologies in rare disease registries
    • Omics data
      • Genome-Phenome Analysis Platform
    • Phenotypic data
      • Registry & Biobank Finder for patient registries
      • Registry common data elements
      • Core Implementation Group
    • Biosamples data
      • Registry & Biobank Finder for biobanks
      • Sample Catalogue
      • Biobank assessment process
      • Biobank Assessment Panel
    • Bioinformatic tools
    • Ethical, Legal and Social Issues (ELSI)
      • Sharing of biosamples and data
      • Standards for informed consent
      • Response to the EU General Data Protection Regulation (GDPR)
    • Patient engagement
  • Resources
    • Newsletters
    • Scientific publications
    • Forms and guides
    • Presentations and flyers
    • Periodic activity reports
    • Glossary
  • For Patients and Families
  • News
  • Events
  • Contact
    • Coordination office
    • Contacts Directory
    • Organisations Directory

Quick links

  • Genome-Phenome Analysis Platform
  • Registry & Biobank Finder
  • Sample Catalogue

Get social

Newsletter sign up

Sign up to our newsletter

RD-Connect

RD-Connect coordination team
Institute of Genetic Medicine
University of Newcastle upon Tyne
International Centre for Life
Newcastle upon Tyne
NE1 3BZ
United Kingdom

Email: Libby Wood (Project Manager)

T: +44 191 241 8621
F: +44 191 241 8770

TOP
/* ----------------------------------------- */ /* Content Template: Loop item in Recent News - start */ /* ----------------------------------------- */ /* ----------------------------------------- */ /* Content Template: Loop item in Recent News - end */ /* ----------------------------------------- */